GLP-1 & compounded medication availability in Alaska (2026)
No state leans on telehealth and mail delivery like Alaska. Distance made remote care normal here years before it was normal anywhere else, and the state’s licensing division publishes some of the plainest telehealth guidance in the country. OrderlyMeds ships to Alaska addresses on our standard national terms. Here is the full picture across all ten product lines we track, including the rows where the honest answer is no.
What ships to Alaska: all ten lines
| Product line | Available in Alaska? | Typical delivery | Notes |
|---|---|---|---|
| GLP-1 (compounded semaglutide) | Yes | 8–10 business days | Delivered by mail to Alaska addresses. |
| GLP-1/GIP (compounded tirzepatide) | Yes | 8–10 business days | Priced nationally. Alaska pays what every state pays. |
| NAD+ | Yes | 8–10 business days | Part of the longevity family; same checkout. |
| Sermorelin | Yes | 8–10 business days | Mail delivery from licensed partner pharmacies. |
| Glutathione | No | N/A | Not on the OrderlyMeds formulary at this time. |
| BPC-157 | Yes | 8–10 business days | Injectable line; its federal record appears below. |
| TB-500 | Yes | 8–10 business days | Injectable line, covered in its own section. |
| KPV | No | N/A | Not available from us in any state; we compound these as injectables only. |
| Epitalon | Yes | 8–10 business days | Injectable line; federal status stated below. |
| MOTS-c | Yes | 8–10 business days | Injectable line whose federal record differs from its siblings. See below. |
The “No” rows are data, not omissions. Alaska facts on this page were last reviewed on November 16, 2026.
Research peptides in Alaska: BPC-157, TB-500, KPV, Epitalon & MOTS-c
OrderlyMeds ships BPC-157, TB-500, Epitalon and MOTS-c to Alaska addresses: four compounded injectables, each on a patient-specific prescription. KPV is the line we do not carry, since our peptides are compounded as injectables only. The sections below give every line its own federal record, shipped or not: the honest version of this answer is per-substance, not per-category.
BPC-157 in Alaska
Carried for Alaska as a compounded injectable, dispensed on a patient-specific prescription. Read both federal facts below.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
TB-500 in Alaska
An Alaska-available compounded injectable under a patient-specific prescription; its record is stated below.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
KPV in Alaska
We do not ship KPV to Alaska or anywhere else, because our peptide lines are injectables only.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
Epitalon in Alaska
Ships to Alaska addresses as a compounded injectable on a patient-specific prescription. The federal facts below still apply in full.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
MOTS-c in Alaska
In the Alaska offering as a compounded injectable, patient-specific prescription required. Its federal record differs from the four above.
FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.
What Alaska’s pharmacy regulators say about compounded medications
Alaska’s licensing division consolidates pharmacy, medical and nursing oversight in one place, and it publishes plain-language guidance on exactly the questions a telehealth patient would ask. The structure for an Alaska order is the standard one: an Alaska-licensed provider, an out-of-state pharmacy registered with the state, and a patient-specific prescription.
Out-of-state pharmacies dispensing to Alaska patients must register with the Alaska Board of Pharmacy and must furnish the board annually with updated licensure information from their home jurisdiction. Source: Alaska Board of Pharmacy — Statutes and Regulations (September 2026).
The board’s published statutes and regulations govern compounding through general practice standards; they contain no GLP-1-specific or peptide-specific restriction. Source: Alaska Board of Pharmacy — Statutes and Regulations (September 2026).
Alaska’s licensing division states that Alaska-licensed physicians, physician assistants, and advanced practice registered nurses may deliver telehealth services, including prescribing, without an initial in-person exam, within their scope of practice; telehealth limits on controlled substances do not reach the non-controlled medications on this page. Source: Alaska Division of Corporations, Business and Professional Licensing — Telehealth Information.
An Alaska order works the way the rest of the country’s do: check eligibility online, complete a telehealth evaluation with an Alaska-licensed provider, and a registered partner pharmacy fills and mails the prescription. Pricing does not change at the border. The published national price is the Alaska price.
Alaska availability FAQs
Is compounded semaglutide available in Alaska?
Yes. It ships to Alaska addresses from licensed partner pharmacies, at the national price: $74/month for the first two months for new customers.
Does OrderlyMeds really deliver to Alaska?
Yes. Our model is mail delivery from licensed partner pharmacies, and Alaska addresses are part of our standard national coverage.
Do I need to see a provider in person first in Alaska?
No. The state's own licensing guidance, cited above, describes telehealth care by Alaska-licensed providers without an initial in-person exam. That is how OrderlyMeds works.
Which research peptides ship to Alaska, and how fast?
BPC-157, TB-500, Epitalon and MOTS-c ship as compounded injectables on patient-specific prescriptions; KPV is not carried. The published delivery window is 8–10 business days from signup, nationwide.
Keep exploring
Ready when you are
See if you’re eligible
Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.
Check eligibilitySecure. Private. No commitment
